Pfizer Inc. (NYSE:PFE) Proposed Acquisition of Metsera, Inc. Conference September 22, 2025 8:00 AM EDT
Company Participants
Francesca DeMartino – Chief Investor Relations Officer
Chris Boshoff – Chief Scientific Officer and President of Research & Development
Andrew Baum – Chief Strategy & Innovation Officer, Executive VP
Jim List
Conference Call Participants
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
David Risinger – Leerink Partners LLC, Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Umer Raffat – Evercore ISI Institutional Equities, Research Division
Kerry Holford – Joh. Berenberg, Gossler & Co. KG, Research Division
Christopher Schott – JPMorgan Chase & Co, Research Division
Terence Flynn – Morgan Stanley, Research Division
Geoffrey Meacham – Citigroup Inc., Research Division
Carter Gould – Cantor Fitzgerald & Co., Research Division
Rajesh Kumar – HSBC Global Investment Research
Courtney Breen – Sanford C. Bernstein & Co., LLC., Research Division
Presentation
Operator
Good day, everyone, and welcome to Pfizer’s Analyst and Investor Call to discuss proposed acquisition of Metsera. Today’s call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma’am.
Francesca DeMartino
Chief Investor Relations Officer
Thank you, and good morning, everyone. I’m Francesca DeMartino, Pfizer’s Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we announced our proposed acquisition of Metsera and its next-generation obesity portfolio. The press release we issued is available on our website at pfizer.com. We will start today’s call with some prepared remarks, followed by a question-and-answer session. I’m joined today by Dr. Chris Boshoff, our Chief Scientific Officer and President of Research and Development; Dr. Andrew Baum, our Chief Strategy and Innovation Officer; and Dr. Jim List, our Chief Internal Medicine Officer.
Read the full article here